论文信息 - DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM). - 字舞流文

DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM).

P. Richardson | B. Holkova | J. Opalinska | R. M. D. Oca | S. Biswas | A. Yeakey | M. Ballas | K. Luptakova | C. Ahlers | I. Gupta | E. Paul | S. Paul | N. Jackson | Thelma Netherway | Chris Shelton | Geraldine Ferron-Brady